In response to the FDA approval of the new dosing regimen of 400 mg every six weeks for pembrolizumab for the treatment of advanced or metastatic anal cancer, the panel requested the addition of the new dosing for this indication.

Submission from Merck (04/29/20) to include the updated dosing recommendations for pembrolizumab, 400 mg every 6 weeks administered as a 30-minute intravenous (IV) infusion until disease progression, unacceptable toxicity, or up to 24 months for the treatment of adult patients with microsatellite instability-high (MSI-H) anal cancer, to ANAL-B in the NCCN Anal Cancer Guidelines.

The panel consensus was to include the new dosing regimen of 400 mg every six weeks for pembrolizumab as an option for advanced or metastatic anal cancer. This is a category 2A recommendation.

Based on the recent FDA approval, the panel consensus was to include the updated dosing recommendations for pembrolizumab, 400 mg every 6 weeks administered as a 30-minute intravenous (IV) infusion until disease progression, unacceptable toxicity, or up to 24 months for the treatment of adult patients with microsatellite instability-high (MSI-H) anal cancer. This is a category 2A recommendation.